ArticleBiomedicines2016
Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization.
Article in Biomedicines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Innate immune cells in chimeric antigen receptor therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Enhancing Oncolytic Virus Therapy with Nanomedicine: A Review of Progress, Challenges, and Future Directions in a New Frontier of Cancer Treatment.International journal of nanomedicine · 2026Review
- Review
- CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives.Biomedicines · 2025Review
- Review
- Advances in cancer vaccines for immunotherapy of prostate cancer.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.Frontiers in immunology · 2023Review
- Poxviruses and the immune system: Implications for monkeypox virus.International immunopharmacology · 2022Review
- Oncolytic Vaccinia Virus in Lung Cancer Vaccines.Vaccines · 2022Review
- Senecavirus A as an Oncolytic Virus: Prospects, Challenges and Development Directions.Frontiers in oncology · 2022Review
- The application of oncolytic viruses in cancer therapy.Biotechnology letters · 2021Review
- Oncolytic virus therapy in cancer: A current review.World journal of virology · 2021Review
- The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering.Future microbiology · 2021Review
- Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity.Molecular cancer therapeutics · 2021Article
- Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.Molecular cancer · 2020Review
- Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.International journal of molecular sciences · 2020Review
- Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.Molecular therapy oncolytics · 2019Review
- Optimizing oncolytic virotherapy in cancer treatment.Nature reviews. Drug discovery · 2019Review
- Oncolytic properties of non-vaccinia poxviruses.Oncotarget · 2018Article
- Oncolytic viruses as engineering platforms for combination immunotherapy.Nature reviews. Cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Oncolytic viruses (OVs) are being extensively studied for their potential roles in the development of cancer therapy regimens. In addition to their direct lytic effects, OVs can initiate and drive systemic antitumor immunity indirectly via release of tumor antigen, as well as by encoding and delivering immunostimulatory molecules. This combination makes them an effective platform for the development of immunotherapeutic strategies beyond their primary lytic function. Engineering the viruses to also express tumor-associated antigens (TAAs) allows them to simultaneously serve as therapeutic vaccines, targeting and amplifying an immune response to TAAs. Our group and others have shown that vaccinating intratumorally with a poxvirus that encodes TAAs, in addition to immune stimulatory molecules, can modulate the tumor microenvironment, overcome immune inhibitory pathways, and drive both local and systemic tumor specific immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.